The South Korean company Samsung is negotiating to acquire the American biotechnology company
BIOGEN IDEC
+9.46%
closure:0
opening:235
Tall:265.54
low:234.36
cycle:—
Page Quote News Graphs Company Profile Recommendations
More articles on the subject:
(NYSE: BIIB) At a value of more than $ 42 billion, the Korea Economics Daily newspaper, based on sources from local investment banks in the country, reported. Following the report, the company jumped 10% in Wall Street trading.
Biogen is now trading at nearly $ 38 billion after the gains, and as it goes through, the deal will be considered the largest in history for a South Korean company. To date, the largest deal made by such a company was also made by Samsung, when in 2016 the subsidiary Samsung Electronics acquired the operations of the electric vehicle manufacturer Herman for $ 8 billion.
Earlier this year, Samsung announced that it would invest more than $ 200 billion over the next three years to expand its operations in biopharmaceuticals, artificial intelligence, semiconductors and robotics – in the post-pandemic era. So far, the two companies have refused to comment on the publications.
These are still dreams for Biogen, with U.S. adulthood sales slower than the company expected, after hospitals across the country complained that drug costs outweighed its benefits, leading to a nearly half-price drop to $ 28.2 thousand per unit.
Comments on the article(0):
Your response has been received and will be published subject to system policies.
Thanks.
For a new response
Your response was not sent due to a communication problem, please try again.
Return to comment
.